Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP3F0D)

Drug Name

Cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea Drug Info

Synonyms

CHEMBL242257; CHEMBL395714; cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea; SCHEMBL3260841; SCHEMBL1066689; SCHEMBL1065034; SCHEMBL1065036; YHZXOUHNBSOYQD-QVTUNDJTSA-N; YHZXOUHNBSOYQD-PIYFJZFMSA-N; BDBM50217474; BDBM50217447; AKOS031057010; AKOS009538033; trans-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea; cis-1-(4-Hydroxy-cyclohexyl)-3-tricyclo[3.3.1.13,7]decan-1-yl-urea

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 11529433
TTD Drug ID: DMP3F0D

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Soluble epoxide hydrolase (EPHX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AR9281	DMJHA6Q	Hypertension	BA00-BA04	Phase 2	[1]
GSK2256294	DM7FN12	Chronic obstructive pulmonary disease	CA22	Phase 1	[2]
13-n-Heptanamidotridec-8(Z)-enoic acid	DM0LGWJ	Discovery agent	N.A.	Investigative	[3]
N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine	DM2CBNG	Discovery agent	N.A.	Investigative	[4]
1-adamantan-1-yl-3-(6-propyloxyhexyl)urea	DMO1L3I	Discovery agent	N.A.	Investigative	[5]
N-adamantyl-N'-cyclohexylurea	DMZ43N1	Discovery agent	N.A.	Investigative	[1]
13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid	DM689TH	Discovery agent	N.A.	Investigative	[3]
N-(3,3-Diphenyl-propyl)-isonicotinamide	DMOXR4K	Discovery agent	N.A.	Investigative	[6]
1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea	DM8SEJP	Discovery agent	N.A.	Investigative	[7]
1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea	DMAZYCD	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Soluble epoxide hydrolase (EPHX2)	TT7WVHI	HYES_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
2	In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31.
3	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
4	A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21.
5	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
6	Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
7	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
8	1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.